Saturday - May 16, 2026
Truqap Recommended by FDA Advisory Committee for PTEN-Deficient Metastatic Hormone-Sensitive Prostate Cancer
May 01, 2026
WILMINGTON, Delaware, May 1 -- AstraZeneca, a biopharmaceutical company, issued the following news release:

* * *

TRUQAP(R) (capivasertib) recommended by FDA Advisory Committee for PTEN-deficient metastatic hormone-sensitive prostate cancer

ODAC overwhelming majority voted that TRUQAP plus abiraterone and ADT

demonstrated a favorable benefit risk profile for patients based on the CAPItello-281 Phase III trial results

First and only . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Name:
What's your
Affiliation		 Government Newspaper / Media Business
Public Policy Individual / Student Educators
Email:
Phone:
Organization, if any:
State/Country you are in:
Additonal questions
or comments:

Click here for more information about our products

Click here for more information about our products